Heart Failure
An Introduction to Heart Failure
Much progress has been made in the management of heart failure in patients with reduced ejection fraction (HFrEF) and the development of therapies for HF with preserved ejection fraction is ongoing. Promising new therapeutics in HF include a dual-acting angiotensin receptor-neprilysin inhibitor, soluble guanylate cyclase (sGC) stimulator and a cardiac myosin activator. It is hoped that gene therapy will be available for patients with HFrEF in the near future.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer- reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
touchCARDIO Future Leaders 2026 Following the successful introduction last year of our touchCARDIO Future Leaders, we are delighted to announce that nominations are now open for the 2026 edition. This initiative celebrates the next generation of pioneers in cardiology, those whose passion, ...
At ACC26, Dr Mardi Gomberg-Maitland presented results from the CADENCE trial, showing how sotatercept significantly improves pulmonary hemodynamics in HFpEF-associated pulmonary hypertension, offering hope for the first targeted therapy in this high-risk population.
Europe loses 1.7 million lives each year to cardiovascular disease, a burden that costs billions and affects millions more. The Safe Hearts Plan sets out an ambitious shift toward prevention, earlier detection and recognition of lifelong genetic risk. As expectations rise, debate is already growing over whether the strategy can translate bold goals into measurable improvements in care and outcomes across the EU.
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...
Heart failure (HF) is a complex and progressive clinical syndrome that significantly impacts morbidity, mortality and quality of life (QoL).1 On a global scale, HF has become an escalating public health concern, affecting more than 64 million individuals in 2017, and this ...
Heart failure (HF) is a global health burden, with a 2019 prevalence of 711.90 per 100,000 population, totalling 56.19 million cases and 5.05 million years lived with disability, despite only modest declines since 1990.1Â Recent years have shown an uptick in prevalence, driven by ageing populations ...
The 2025 American Heart Association (AHA) Scientific Sessions (7–10 November; New Orleans, LA, USA) offered a comprehensive overview of the evolving landscape of cardiovascular medicine. This year’s research showcased pivotal trials spanning indications, including hypercholesterolemia, hypertrophic cardiomyopathy, amyloidosis, severe hypertriglyceridaemia, hypertension, ...
In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related diseases. From understanding the science behind cellular senescence to how senolytic drugs work and what early clinical trials reveal, this episode explores an exciting frontier in longevity medicine.
S3E1_What impact does sleep have on physicians and their patients? We all know sleep is important, but what happens when physicians don’t get enough? In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from ...
Late-breaking data from ESC 2025 are set to reshape daily cardiology practice, with Dr José Luis Merino highlighting trials that challenge long-standing use of beta blockers, underscore the value of potassium optimization in ICD patients, and caution against routine aspirin in anticoagulated individuals, while also pointing to artificial intelligence as an emerging tool in clinical decision-making.
New perspectives from ESC 2025 point to cryoablation as a streamlined and safer option for managing atrial fibrillation in heart failure, offering the potential for earlier treatment and broader access in busy healthcare systems.
The POLAR-HF trial shows that early, simplified pulmonary vein isolation is safe and effective in patients with atrial fibrillation and reduced ejection fraction, reinforcing the importance of timely rhythm control without the need for complex ablation strategies.
Cardiac implantable electronic devices are undergoing rapid change, with conduction system pacing and new strategies for resynchronization therapy challenging long-standing standards. At ESC 2025, Dr Haran Burri highlights late-breaking trial data that could redefine best practice and underscores the importance of careful technique and training to translate these advances into meaningful patient benefit.
July 2025 marked continued progress in cardiovascular innovation, with notable regulatory decisions and clinical trial milestones. Approvals, designations, and data readouts during the month highlight the field’s ongoing shift toward targeted therapies, gene-based interventions, and outcome-driven evidence. These developments reflect growing momentum in addressing complex and underserved cardiovascular conditions.
Gene therapies are redefining the landscape of cardiovascular treatment, offering targeted solutions for conditions like heart failure, hypertrophic cardiomyopathy, and amyloidosis. Using advanced techniques such as viral vector delivery, RNA modulation, and CRISPR-based editing, these therapies aim to address root genetic causes. While challenges in delivery and safety remain, early clinical data signal a promising shift toward more durable and precise cardiac interventions.
In this Q&A, Dr Zheng reflects on the power of collaborative mentorship, the creative rewards of scientific discovery, and the promise of precision medicine in reshaping the future of cardiomyopathy care
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
